BeiGene (BGNE, Financial) saw its stock price rise over 2.3% in pre-market trading, reaching $240.9. The increase follows the U.S. commercial launch of TEVIMBRA® (tislelizumab), also known as 百泽安® in Chinese, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have undergone prior systemic chemotherapy excluding PD-1/L1 inhibitors.
The U.S. Food and Drug Administration (FDA) is currently reviewing TEVIMBRA® for potential use as a first-line treatment for patients with locally advanced unresectable or metastatic ESCC. Additionally, the FDA is assessing its application in treating locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma as a first-line treatment option.
